Linsitinib (OSI-906)

For research use only. Not for use in humans.

Catalog No.S1091

78 publications

Linsitinib (OSI-906) Chemical Structure

Molecular Weight(MW): 421.49

Linsitinib (OSI-906) is a selective inhibitor of IGF-1R with IC50 of 35 nM in cell-free assays; modestly potent to InsR with IC50 of 75 nM, and no activity towards Abl, ALK, BTK, EGFR, FGFR1/2, PKA etc. Phase 3.

Size Price Stock Quantity  
10mM (1mL in DMSO) USD 190 In stock
USD 170 In stock
USD 270 In stock
USD 720 In stock
Bulk Discount

Free Overnight Delivery on orders over $ 500
Next day delivery by 10:00 a.m. Order now.

Selleck's Linsitinib (OSI-906) has been cited by 78 publications

Purity & Quality Control

Choose Selective IGF-1R Inhibitors

Biological Activity

Description Linsitinib (OSI-906) is a selective inhibitor of IGF-1R with IC50 of 35 nM in cell-free assays; modestly potent to InsR with IC50 of 75 nM, and no activity towards Abl, ALK, BTK, EGFR, FGFR1/2, PKA etc. Phase 3.
Targets
IGF-1R [1]
(Cell-free assay)
Insulin Receptor [1]
(Cell-free assay)
IRR [1]
(Cell-free assay)
35 nM 75 nM 75 nM
In vitro

OSI-906 inhibits IGF-1R autophosphorylation and activation of the downstream signaling proteins Akt, ERK1/2 and S6 kinase with IC50 of 0.028 to 0.13 μM. OSI-906 enables an intermediate conformation of the target protein through interactions with the C-helix. OSI-906 displays favorable metabolic stability in liver microsomes. OSI-906 fully inhibits both IR and IGF-1R phosphorylation at a concentration of 1 μM. OSI-906 inhibits proliferation of several tumor cell lines including non-small-cell lung cancer and colorectal cancer (CRC) tumor cell line with EC50 of 0.021 to 0.810 μM. [1]

Cell Data
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID
A4-Fuk NUPQc5FsT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NHzQTJBKSzVyPUCuNFI5ODZizszN NX3WeJpOW0GQR1XS
KS-1 M{PVN2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M{\ZNmlEPTB;MD6wN|g{PSEQvF2= MVzTRW5ITVJ?
TE-11 NFPi[phIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M3rBTWlEPTB;MD6wO|gzOiEQvF2= MnzJV2FPT0WU
EW-1 MoLkS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MVXJR|UxRTBwMEi1PFUh|ryP NInYcpRUSU6JRWK=
HMV-II M2DoXGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MW\JR|UxRTBwMEi4OFYh|ryP NXrXW406W0GQR1XS
COLO-205 MVnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NF7K[HNKSzVyPUCuNVA1PTRizszN MkPXV2FPT0WU
ES1 MonLS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MVXJR|UxRTBwMUC2PVYh|ryP M2TIV3NCVkeHUh?=
GDM-1 M{WzVGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M1LGbGlEPTB;MD6xN|Y4OiEQvF2= MXLTRW5ITVJ?
ML-2 MVfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NXG2S2w6UUN3ME2wMlE2QDl4IN88US=> NWWzeYR{W0GQR1XS
Saos-2 M33SRWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NYDwZpBQUUN3ME2wMlE3PTJ4IN88US=> M3zPO3NCVkeHUh?=
NCI-H1355 M2DRS2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MVjJR|UxRTBwMUixN|Uh|ryP M1H0ZnNCVkeHUh?=
G-401 MmH1S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NEXkTGFKSzVyPUCuNVgzOyEQvF2= MWXTRW5ITVJ?
EW-16 M3zyZWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MXzJR|UxRTBwMUi3O|ch|ryP NFTjPYVUSU6JRWK=
EW-7 M{jtOWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NGjERVVKSzVyPUCuNVg5QDFizszN NUC3bXBXW0GQR1XS
NCI-H727 MmfrS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MV3JR|UxRTBwMUm3PVQh|ryP M3;uZXNCVkeHUh?=
LCLC-97TM1 MWPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M4\xUmlEPTB;MD6yNFk2PSEQvF2= MVjTRW5ITVJ?
NCI-H650 M3HNV2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M13STGlEPTB;MD6yNVM5PCEQvF2= MUTTRW5ITVJ?
NCI-H2122 MmXPS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MnLYTWM2OD1yLkKzNlk6KM7:TR?= MkHaV2FPT0WU
SK-N-DZ M{TQdmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MWDJR|UxRTBwMkO2PVgh|ryP M1rZWnNCVkeHUh?=
HT-29 MnTiS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MmrHTWM2OD1yLkK0NlQ5KM7:TR?= M4TtfnNCVkeHUh?=
LB771-HNC Mm\GS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NUnMS4FFUUN3ME2wMlI2QTF3IN88US=> M{jmXHNCVkeHUh?=
HT-144 NFzke4lIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= Mk\qTWM2OD1yLkK2NVkyKM7:TR?= NGGyfI1USU6JRWK=
LAN-6 MoHxS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NIT5RmlKSzVyPUCuNlY{PDhizszN MkfDV2FPT0WU
EW-18 MXLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M1qyfWlEPTB;MD6yO|AxOSEQvF2= NXvrT2s4W0GQR1XS
LS-1034 NWnYUZdNT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MnPLTWM2OD1yLkK3NVMzKM7:TR?= M1PERnNCVkeHUh?=
EW-11 M2LUSGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MkfVTWM2OD1yLkK4OFMzKM7:TR?= M{fHZnNCVkeHUh?=
SNU-C1 MYLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M4HBWGlEPTB;MD6yPVMyOyEQvF2= Mn\VV2FPT0WU
RS4-11 MYPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M2HEdGlEPTB;MD6zN|c2QCEQvF2= NEfUSGlUSU6JRWK=
ES4 NHTVeI5Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M4jKcGlEPTB;MD60NVA{QCEQvF2= MYfTRW5ITVJ?
COLO-320-HSR Mn[zS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NHu4RW9KSzVyPUCuOFE{PjhizszN M1XHbnNCVkeHUh?=
NB10 NGLxT|FIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NGjYdGRKSzVyPUCuOFU1OzdizszN MnLIV2FPT0WU
BFTC-905 MVjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NGGycpNKSzVyPUCuOFY4PThizszN MUjTRW5ITVJ?
A375 MWfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MonZTWM2OD1yLkS3OlE4KM7:TR?= MX7TRW5ITVJ?
SJRH30 NYDhVpFjT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NUjrVVR5UUN3ME2wMlUxQDJ{IN88US=> NEDXfVNUSU6JRWK=
NOS-1 NV\IZnZtT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= Mm[2TWM2OD1yLkWyNlY4KM7:TR?= M{jld3NCVkeHUh?=
SIG-M5 MnTUS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M1uyNGlEPTB;MD61N|U2PyEQvF2= M{fhUXNCVkeHUh?=
DOK NYPOd2tQT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= Mnz4TWM2OD1yLkW1OkDPxE1? M3qycXNCVkeHUh?=
NB69 MULHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NXz4RmxXUUN3ME2wMlU5OjV5IN88US=> NUHNRYZ{W0GQR1XS
SK-NEP-1 MVXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MUXJR|UxRTBwNkCyN|Yh|ryP MVfTRW5ITVJ?
SK-MM-2 MYPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M13YVmlEPTB;MD62OVQ6OSEQvF2= MXLTRW5ITVJ?
NCI-H358 NYHFR21JT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MVjJR|UxRTBwNkewPFIh|ryP MoDUV2FPT0WU
RH-1 NYqxPXRlT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MkixTWM2OD1yLke0PFU6KM7:TR?= MojFV2FPT0WU
NH-12 NH7lTldIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NUD5R|VEUUN3ME2wMlc3ODR4IN88US=> MVPTRW5ITVJ?
TE-12 Mn;RS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NVHkS|hiUUN3ME2wMlc3PDh4IN88US=> MoXxV2FPT0WU
COLO-668 NV3tVHRsT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MoPVTWM2OD1yLki0OlY3KM7:TR?= MVHTRW5ITVJ?
PANC-08-13 NGfuZo9Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MnW0TWM2OD1yLki2N|c4KM7:TR?= MYrTRW5ITVJ?
HCC2998 NFPFfXlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NXz6O4l7UUN3ME2wMlg5OjZ|IN88US=> M{HWdXNCVkeHUh?=
ABC-1 MXrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NYXpeFU5UUN3ME2wMlkxOzV{IN88US=> MkjRV2FPT0WU
ES6 M4SzNmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MnHoTWM2OD1yLkmxNFY3KM7:TR?= NF\vVFZUSU6JRWK=
SNU-387 NETtW4ZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MkjZTWM2OD1yLkm5N|k{KM7:TR?= MYLTRW5ITVJ?
CMK NVnVOolPT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MkjvTWM2OD1yLkm5PVI6KM7:TR?= MVvTRW5ITVJ?
SJSA-1 Ml3MS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NWTMUpZZUUN3ME2xMlA{PjV|IN88US=> MVfTRW5ITVJ?
SIMA MXnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M{fQUWlEPTB;MT6wOlgzPSEQvF2= Ml;TV2FPT0WU
ES3 M2q0NWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M{DVWGlEPTB;MT6xNlI6PyEQvF2= NV3XUVR7W0GQR1XS
IGROV-1 MWPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M3e2PGlEPTB;MT6xOVQ1PCEQvF2= MkixV2FPT0WU
MEL-JUSO NWXyZm1VT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M{nxR2lEPTB;MT6xOVc2QSEQvF2= MWnTRW5ITVJ?
T84 MlzaS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M1XGcGlEPTB;MT6yNFkyPCEQvF2= MnzNV2FPT0WU
CAL-85-1 MX;Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M2LoWmlEPTB;MT6yN|E{QCEQvF2= MV\TRW5ITVJ?
RD Mnn3S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NIDxXHlKSzVyPUGuNlY1PTVizszN M{fuOHNCVkeHUh?=
TE-8 MVPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NUPpN5RQUUN3ME2xMlMyPDZ{IN88US=> MYXTRW5ITVJ?
L-363 MYnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MUTJR|UxRTFwM{SyNFgh|ryP NVjFVHhmW0GQR1XS
EKVX MVHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MoG5TWM2OD1zLkO0OVY5KM7:TR?= MXnTRW5ITVJ?
SK-MEL-3 MnT5S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MWLJR|UxRTFwNEi1OVYh|ryP MoDvV2FPT0WU
TGBC24TKB M1Hmdmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NUXHOHg2UUN3ME2xMlUxOTl|IN88US=> M1LEUnNCVkeHUh?=
NCI-H1770 M{n4fmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M{Lr[GlEPTB;MT61NVEyOyEQvF2= MWLTRW5ITVJ?
HuH-7 MX7Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NVn6dWh2UUN3ME2xMlYxODl6IN88US=> NECxW|hUSU6JRWK=
HL-60 NX;1[JBWT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MXfJR|UxRTFwNk[5Nlgh|ryP NXvDRm5iW0GQR1XS
TE-1 MYDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MV7JR|UxRTFwN{C5OFUh|ryP Mn\EV2FPT0WU
LC-2-ad M3\sWGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MmT6TWM2OD1zLkezPFg4KM7:TR?= M4m2V3NCVkeHUh?=
LB647-SCLC M4PpNmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MWLJR|UxRTFwN{[1PFMh|ryP MoPYV2FPT0WU
NCI-H2171 MUDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MlXuTWM2OD1zLke3O|E3KM7:TR?= MlPpV2FPT0WU
SK-PN-DW NYnQSlN[T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NHLBOWNKSzVyPUGuPVEzQThizszN NULoVYZHW0GQR1XS
MC-IXC NEjQfoRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NYHtTohJUUN3ME2xMlk5QThizszN MWfTRW5ITVJ?
LS-513 MnP5S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? Ml7ITWM2OD1{LkC1N|A2KM7:TR?= MX;TRW5ITVJ?
EW-3 MYPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MWXJR|UxRTJwMEm4OFQh|ryP NWPidYlDW0GQR1XS
OPM-2 NInaSGhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M2nDZWlEPTB;Mj6xNFIh|ryP NETsUW1USU6JRWK=
LP-1 MlfaS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NEfkWmdKSzVyPUKuNlU5ODdizszN MX;TRW5ITVJ?
LU-134-A NEPOOJpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M3XhUWlEPTB;Mj6yO|ch|ryP MYHTRW5ITVJ?
CP66-MEL NV65NIZXT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= Mk\WTWM2OD1{LkK5NFE1KM7:TR?= M{DyR3NCVkeHUh?=
HCC1143 Mn2yS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MlHSTWM2OD1{LkS1N|Y5KM7:TR?= NVv2UWxIW0GQR1XS
LOXIMVI NXvMbYdJT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M4KzVWlEPTB;Mj62NFIyKM7:TR?= MYfTRW5ITVJ?
TE-10 MUPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NGrKOHNKSzVyPUKuO|A5OzhizszN NHi4ZVRUSU6JRWK=
NCI-H1882 NX\tXGx3T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MU\JR|UxRTJwN{WyNlch|ryP M{TWb3NCVkeHUh?=
CHP-126 NVTkeHFVT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MnjTTWM2OD1{Lke2N|E4KM7:TR?= MoH2V2FPT0WU
NCI-H1623 NGTWW3VIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MorsTWM2OD1{LkmyNFI1KM7:TR?= M1m5UnNCVkeHUh?=
GB-1 NIixcWtIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MnHrTWM2OD1{LkmzOFA1KM7:TR?= NUTkcG9QW0GQR1XS
RCC10RGB MlTvS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NV[w[mY1UUN3ME2yMlk2OjhzIN88US=> NFXMUmdUSU6JRWK=
NCI-H2141 NI[3WHpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MWLJR|UxRTJwOU[4PVYh|ryP NHXFcXpUSU6JRWK=
GI-ME-N NUTKdJBuT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MXHJR|UxRTNwMEC1OlUh|ryP MnTmV2FPT0WU
NCI-H526 NVXueINRT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MVTJR|UxRTNwMESwPFUh|ryP Mlv1V2FPT0WU
NCI-H747 NWXPc2JxT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M3XYPWlEPTB;Mz6wOFk6OiEQvF2= M1yyUHNCVkeHUh?=
SNU-423 NHLvOnpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MWTJR|UxRTNwMkCzNVMh|ryP M1rvN3NCVkeHUh?=
A427 NV3yOmpIT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MVnJR|UxRTNwMkW2PVkh|ryP M3XOS3NCVkeHUh?=
CAL-12T NIDZSnlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MUjJR|UxRTNwNEC3NVMh|ryP M2HxRXNCVkeHUh?=
LU-99A MUPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NVzq[YpGUUN3ME2zMlQ4OTB3IN88US=> MU\TRW5ITVJ?
MS-1 MXjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MY\JR|UxRTNwNUO0Nlkh|ryP MXTTRW5ITVJ?
SK-LU-1 NV\XbWpbT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MnS4TWM2OD1|Lke2Nlk2KM7:TR?= M{m5WXNCVkeHUh?=
SW837 MWXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M3vuVmlEPTB;Mz63OlM{OyEQvF2= M4\Ke3NCVkeHUh?=
ES8 MnL1S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M2PaPGlEPTB;Mz64N|g4PyEQvF2= M1rEUHNCVkeHUh?=
MZ2-MEL NGrPV2lIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MnTmTWM2OD1|LkmyNFg3KM7:TR?= M4rPWXNCVkeHUh?=
TGW M1TNPGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NXKzelF{UUN3ME20MlAyOzFzIN88US=> NX3WXYF3W0GQR1XS
GP5d NFHiTItIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NG\X[JRKSzVyPUSuNFU{PjJizszN NWGyVlNrW0GQR1XS
BB49-HNC MlvjS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NHnkWnNKSzVyPUSuNVUzOTNizszN MVPTRW5ITVJ?
NB13 MVrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NInDWoRKSzVyPUSuNlY5QDdizszN NIjXO4ZUSU6JRWK=
NTERA-S-cl-D1 Ml;XS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? Mo\HTWM2OD12LkK4OlE2KM7:TR?= NUnPRnQ{W0GQR1XS
NCI-H1648 NF:1VmtIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M1vwc2lEPTB;ND6yPVgyQSEQvF2= MWrTRW5ITVJ?
LCLC-103H MYPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M{DxOmlEPTB;ND6zNlE6PSEQvF2= Ml[zV2FPT0WU
LS-411N NUPhUWdkT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MYjJR|UxRTRwNES4PFUh|ryP M2jvVnNCVkeHUh?=
NCI-H1092 Mn65S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NFTuZnFKSzVyPUSuOFU3QDdizszN Ml:wV2FPT0WU
PANC-10-05 NILPbYVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NHnx[WdKSzVyPUSuOlk5PCEQvF2= MWXTRW5ITVJ?
DK-MG NGTtRZVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MmPyTWM2OD12LkiwPVM{KM7:TR?= Mo\JV2FPT0WU
OVCAR-5 MlryS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NU\jUXI3UUN3ME20MlgyOjJ4IN88US=> NXv3NnFLW0GQR1XS
CAL-39 M1;u[Gdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M2XDPGlEPTB;ND64O|Y4KM7:TR?= M{\We3NCVkeHUh?=
TE-441-T NWWwSJc{T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M{DhXGlEPTB;ND65NFU{PyEQvF2= MUjTRW5ITVJ?
MOLT-16 MlL4S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M4PIPWlEPTB;ND65OVI2OyEQvF2= Mlv1V2FPT0WU
MCF7 MonvS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MUnJR|UxRTVwMUS1NVch|ryP NETWeFZUSU6JRWK=
CAPAN-1 MXvHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MW\JR|UxRTVwMkW3NFch|ryP NF\qb3RUSU6JRWK=
PSN1 M{[2WWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NWrTcYhTUUN3ME21MlI4OjN3IN88US=> MnzhV2FPT0WU
NCI-H292 NVHtXIZvT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MWXJR|UxRTVwM{CwOFQh|ryP NHHiWXpUSU6JRWK=
CPC-N NHW1[FRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M13YZmlEPTB;NT6zPVQyQSEQvF2= M4LaWHNCVkeHUh?=
DoTc2-4510 M1HEdGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M{j5Z2lEPTB;NT60OVM4OSEQvF2= NV;RdolwW0GQR1XS
LB1047-RCC MmD2S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M1\6b2lEPTB;NT61OVk{OyEQvF2= MUfTRW5ITVJ?
MHH-ES-1 MmX4S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NGrxb2xKSzVyPUWuOVk6ODdizszN MXPTRW5ITVJ?
NMC-G1 NXzjdlVoT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MYLJR|UxRTVwN{CyNlch|ryP MUHTRW5ITVJ?
SW1710 NXLafHBLT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NG\DfFFKSzVyPUWuO|Q4PTFizszN NYf4OphCW0GQR1XS
YAPC MojlS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NXnOcm85UUN3ME21Mlc3OjBzIN88US=> MYDTRW5ITVJ?
22RV1 M3\ne2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NIW1dlVKSzVyPUWuPFAxOTlizszN NELCeHdUSU6JRWK=
COLO-679 NVPaUXJ[T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MYHJR|UxRTVwOEi5OFgh|ryP M2XQd3NCVkeHUh?=
TCCSUP MlXjS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MkTuTWM2OD13LkmzNlU6KM7:TR?= MknTV2FPT0WU
C2BBe1 NEnpeZJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MlHuTWM2OD13LkmzPVch|ryP M1;TPHNCVkeHUh?=
TE-15 MXjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MXHJR|UxRTZwME[2NFUh|ryP NEPpe|FUSU6JRWK=
SCLC-21H NYiz[HR2T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M1:4V2lEPTB;Nj6xNFg1OyEQvF2= M1z0e3NCVkeHUh?=
EoL-1-cell NGOwUVhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NVzyXGxSUUN3ME22MlE3PTZ|IN88US=> MmTsV2FPT0WU
NKM-1 MlWyS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MnPITWM2OD14LkG2O|Eh|ryP MkHrV2FPT0WU
NCI-H1304 NYSyeXB6T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M2XXfWlEPTB;Nj6yO|QzQCEQvF2= NEDNVGRUSU6JRWK=
NB6 M2DSfmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M{f6N2lEPTB;Nj6yPVYzOiEQvF2= NXnieJl5W0GQR1XS
NALM-6 NUTYfWo3T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MULJR|UxRTZwM{OyN{DPxE1? NYrjR3l3W0GQR1XS
NCI-H522 M1vVWmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M17Ye2lEPTB;Nj6zN|MxPiEQvF2= MmHYV2FPT0WU
MV-4-11 NXLoZnBNT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= Mn;0TWM2OD14LkO3NFc6KM7:TR?= NI\yeXRUSU6JRWK=
LB2241-RCC NIXQdW9Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= Mki1TWM2OD14LkO4OlY4KM7:TR?= NXHHS5I1W0GQR1XS
NCI-H1417 NXTI[GtxT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MVPJR|UxRTZwNEC4OFch|ryP NYKwVWw1W0GQR1XS
HT-1197 M3rzfmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MkfqTWM2OD14LkW3NVIzKM7:TR?= MWjTRW5ITVJ?
P30-OHK M1vqOWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NHK2WHdKSzVyPU[uOlI4PyEQvF2= NXv0Z5l3W0GQR1XS
ALL-PO MmDuS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MXXJR|UxRTZwN{G5NVYh|ryP MlXiV2FPT0WU
OVCAR-4 Mmf5S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NXnPN|A3UUN3ME22Mlc2PDB3IN88US=> NIfQVJZUSU6JRWK=
HCC2157 NXm2[G5jT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MUfJR|UxRTZwN{e0O|Uh|ryP NHrGdXdUSU6JRWK=
NCI-H838 M122PGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MmPxTWM2OD14Lkm2OFkh|ryP M2fXNHNCVkeHUh?=
NCI-H1299 M{\KPGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NX:2eoJmUUN3ME22Mlk4ODlizszN MXvTRW5ITVJ?
SW954 NIfkU2JIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= Ml7KTWM2OD15LkKwNFY5KM7:TR?= NVfXRWJjW0GQR1XS
NCI-H441 MYDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M3zFfGlEPTB;Nz6zOFA3PSEQvF2= NE\CdYVUSU6JRWK=
SK-MEL-2 M4rnOmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NVLF[5AzUUN3ME23MlQ5Ozd|IN88US=> NIfnV2lUSU6JRWK=
KARPAS-45 NYjPTlhyT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MUHJR|UxRTdwNkW5Nlkh|ryP NGSxe3pUSU6JRWK=
CAL-54 NHXidJJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NWDmSI9zUUN3ME23MlgzQTd5IN88US=> M1TVR3NCVkeHUh?=
KYSE-180 MWXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M1\NdGlEPTB;Nz64PFk1OSEQvF2= NIPHWZVUSU6JRWK=
NCI-H187 NW\t[ZE6T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NVnM[mJFUUN3ME23Mlk2QTR5IN88US=> NULtOXRZW0GQR1XS
RT-112 NGDSZ45Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M1SwN2lEPTB;OD6wPVY4PyEQvF2= MoPjV2FPT0WU
NCI-H1437 NUftPGxJT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NYf4ZoJRUUN3ME24MlA6Pzl3IN88US=> NG\UcIlUSU6JRWK=
SNU-449 NWnSOWxpT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MVLJR|UxRThwMkiyO|Ih|ryP MnnhV2FPT0WU
HCC1187 MlzpS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MXnJR|UxRThwMkmzPVEh|ryP M4WwPHNCVkeHUh?=
NCI-H2030 NWOycnlTT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MVjJR|UxRThwM{e3NVQh|ryP MmW4V2FPT0WU
HuO-3N1 NY\pSW1HT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NHHjWlFKSzVyPUiuN|c5PDRizszN M2nMZXNCVkeHUh?=
COLO-792 NH;qeGhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MWDJR|UxRThwNEG1Nlch|ryP M1fqTHNCVkeHUh?=
MIA-PaCa-2 MXnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M3L0O2lEPTB;OD64OVUxQCEQvF2= NFXWSYNUSU6JRWK=
SK-N-FI Mn6wS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M37tbGlEPTB;OT6wOFI2KM7:TR?= NFL4PJRUSU6JRWK=
MMAC-SF M4H0[mdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MoC4TWM2OD17LkC5O|UyKM7:TR?= M1vpXnNCVkeHUh?=
NCI-H28 MX\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NHK4WopKSzVyPUmuNVA1PjlizszN NHP3UnhUSU6JRWK=
ETK-1 MU\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MlTuTWM2OD17LkK5PVc1KM7:TR?= NIDCboJUSU6JRWK=
NCI-H1993 MWnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NETMcpNKSzVyPUmuOFQzPjFizszN MnnBV2FPT0WU
no-11 NHvMem1Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M3rIV2lEPTB;OT60O|EzKM7:TR?= NVPhVlFlW0GQR1XS
ChaGo-K-1 NG\uOXlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MVzJR|UxRTlwNUG1PFMh|ryP NY\DUXY3W0GQR1XS
NCCIT MU\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NFf4dJhKSzVyPUmuOVMyPjlizszN MnGzV2FPT0WU
SAS M37wb2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M1XnbWlEPTB;MUCuNlQ5KM7:TR?= NG\wVGlUSU6JRWK=
A673 Mn;qS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M3f2NmlEPTB;MUCuN|cxPCEQvF2= MW\TRW5ITVJ?
NCI-H1522 M3nKeGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NE\TSHpKSzVyPUGwMlM4ODdizszN NULlOIlHW0GQR1XS
NCI-H810 NUjxR4xnT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NGPaT|hKSzVyPUGwMlM6ODdizszN M17qXnNCVkeHUh?=
IST-MES1 M3\QNmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M4\2eGlEPTB;MUCuOFU3PCEQvF2= NX;jU3NPW0GQR1XS
GR-ST MljLS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NEf6XlVKSzVyPUGwMlUxOjRizszN NGLISWhUSU6JRWK=
SUP-T1 Ml;kS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M2roe2lEPTB;MUCuO|MyPyEQvF2= MV7TRW5ITVJ?
NB5 MVTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M4PZUGlEPTB;MUCuPVAzOiEQvF2= NXPzbYczW0GQR1XS
MZ1-PC MV3Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M4LDOmlEPTB;MUCuPVU4OSEQvF2= MkfIV2FPT0WU
SK-CO-1 Mm\vS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MlfuTWM2OD1zMD65PVMyKM7:TR?= M3PDPXNCVkeHUh?=
Capan-2 NUW4OlJwT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NVflWoxOUUN3ME2xNU4{OTl6IN88US=> MoTQV2FPT0WU
697 MYDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NG[z[W1KSzVyPUGxMlY4PTdizszN M2HCcnNCVkeHUh?=
REH M3zJbmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NWX3W3VDUUN3ME2xNU44PDVzIN88US=> NVXSToJuW0GQR1XS
GI-1 NGSzTYVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M1LvVGlEPTB;MUGuPFYyPSEQvF2= M{LRfXNCVkeHUh?=
BB65-RCC MoT6S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NV;n[|hEUUN3ME2xNk4xQTF4IN88US=> NVjRZmpnW0GQR1XS
NCI-H1651 Mn24S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MXXJR|UxRTF{LkK0O|gh|ryP MWDTRW5ITVJ?
NCI-H1618 MWjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MoDSTWM2OD1zMj6zPVc3KM7:TR?= MUnTRW5ITVJ?
NCI-H2081 NIPoNVhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NHm4XIhKSzVyPUGyMlYyPDFizszN M{j0N3NCVkeHUh?=
GCIY NFTRTIFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M4XMe2lEPTB;MUKuO|IyOyEQvF2= MYfTRW5ITVJ?
NY NYnab5g6T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NFPjSnZKSzVyPUGzMlA3PDNizszN NF7xVVNUSU6JRWK=
PANC-03-27 M2\ZbWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M1mySWlEPTB;MUOuNFgxPyEQvF2= NYDFZ246W0GQR1XS
BHY MWjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NEHGblBKSzVyPUGzMlIyOjFizszN M134eXNCVkeHUh?=
SK-OV-3 M{fWOWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NHLUZ2hKSzVyPUGzMlM4PjNizszN M1rQd3NCVkeHUh?=
5637 NID3RZlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NVTsd3Y1UUN3ME2xN{44PzV7IN88US=> Mmr4V2FPT0WU
LC-1F MXzHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NIP0SnpKSzVyPUG0MlA{PTZizszN M4O0cnNCVkeHUh?=
SNB75 M2W4VWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NXvJdWZrUUN3ME2xOE4xOzh|IN88US=> M1vmNXNCVkeHUh?=
CHP-212 NGXGN|VIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M1\4T2lEPTB;MUSuNFQ3PCEQvF2= NGHVbZJUSU6JRWK=
HT-1376 MlvtS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NHG5cW1KSzVyPUG0MlEyOjZizszN M4\T[XNCVkeHUh?=
MONO-MAC-6 M1HEd2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M1nRO2lEPTB;MUSuNVUxOiEQvF2= NVfVZohoW0GQR1XS
CA46 NFP0S49Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MkjNTWM2OD1zND6xPFI4KM7:TR?= NG\WUI9USU6JRWK=
SCC-15 MVrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? Mm\VTWM2OD1zND61OVg{KM7:TR?= NVnZeXRnW0GQR1XS
ATN-1 M3LMVmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MmLlTWM2OD1zND62OlI4KM7:TR?= MmjRV2FPT0WU
NCI-H2405 M2fwWGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MkPwTWM2OD1zND64NVU4KM7:TR?= MknvV2FPT0WU
NCI-H716 NYewcHJlT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MkL0TWM2OD1zND64OFk{KM7:TR?= NH3pNllUSU6JRWK=
SW620 NYLBOoN2T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M2PvNmlEPTB;MUSuPVAyPCEQvF2= MmnaV2FPT0WU
NCI-H226 M1TZS2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NU\4N2FpUUN3ME2xOE46ODh3IN88US=> M3X3b3NCVkeHUh?=
SW962 NHXIVHFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NUT5SY5oUUN3ME2xOE46PDN{IN88US=> NHXNOIFUSU6JRWK=
KYSE-150 MVnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NGPlTYtKSzVyPUG0Mlk2PSEQvF2= NELDVGhUSU6JRWK=
OCUB-M M2H0UGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NXLzfHp7UUN3ME2xOE46QDh|IN88US=> M1uwZnNCVkeHUh?=
ES7 MX7Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M1nhUmlEPTB;MUWuNFk5PCEQvF2= NGLjVHVUSU6JRWK=
SW1463 MVXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MXXJR|UxRTF3LkSyNlMh|ryP MWLTRW5ITVJ?
CAKI-1 MnPwS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NUnMb5o6UUN3ME2xOU42OzR4IN88US=> MUPTRW5ITVJ?
MKN28 M1rHNmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NF7ublRKSzVyPUG1MlU1PzlizszN NXv3PWFKW0GQR1XS
SW13 Mnm4S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NXXF[mdEUUN3ME2xOU43OThizszN Mn35V2FPT0WU
A3-KAW NXz2XnBrT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MXzJR|UxRTF3Lkm2PVch|ryP NULQV5V5W0GQR1XS
LU-65 MmXiS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MYjJR|UxRTF3Lkm3Olgh|ryP M4DTTHNCVkeHUh?=
Calu-1 Mmf1S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MnHWTWM2OD1zNj6wN|Y5KM7:TR?= Ml\4V2FPT0WU
ST486 NWDt[nhPT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MWHJR|UxRTF4LkC0N|Eh|ryP NX;jRYF1W0GQR1XS
BB30-HNC NYnq[GJZT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NEfVdnNKSzVyPUG2MlEzPDZizszN MXvTRW5ITVJ?
EGI-1 Ml7zS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M1HHb2lEPTB;MU[uOFQ3KM7:TR?= MnLnV2FPT0WU
SH-4 NFrwVlFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M{S3[mlEPTB;MU[uOFc{OSEQvF2= MlW0V2FPT0WU
MN-60 M2SxfWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 Ml\iTWM2OD1zNz6yNlk4KM7:TR?= MXXTRW5ITVJ?
MPP-89 MXLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MkXpTWM2OD1zNz6yOFU6KM7:TR?= M17KdHNCVkeHUh?=
A2780 M37jTmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MVTJR|UxRTF5LkSxN|kh|ryP NFm0XWpUSU6JRWK=
Daoy NXrqS2Z[T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NFPUZlFKSzVyPUG3MlQ3QTVizszN Mn;2V2FPT0WU
NCI-H2126 MlLGS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NYjoOG9XUUN3ME2xO{41PzdzIN88US=> M3TXZ3NCVkeHUh?=
NCI-H1563 MXvHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NVTYb4NDUUN3ME2xO{41QTF5IN88US=> MlfnV2FPT0WU
8-MG-BA MVHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MlTBTWM2OD1zNz62OlQ5KM7:TR?= MXvTRW5ITVJ?
786-0 MWHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MonWTWM2OD1zNz64N|U{KM7:TR?= M2LvOnNCVkeHUh?=
AM-38 NFSzOIJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MX;JR|UxRTF5LkmzNFYh|ryP MV7TRW5ITVJ?
COLO-824 MVnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NHPrWXdKSzVyPUG4MlQ1OzZizszN MUjTRW5ITVJ?
SK-MEL-30 MX\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M{jkcWlEPTB;MUiuOVA5OiEQvF2= MkLGV2FPT0WU
CESS MlnpS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NGjJfJFKSzVyPUG4Mlc3ODlizszN NWHoUYlpW0GQR1XS
BL-70 MUTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MnH2TWM2OD1zOD64NVU3KM7:TR?= M1nO[3NCVkeHUh?=
NCI-H2170 NV3YN2VGT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NU\FZ3hvUUN3ME2xPE46OTd7IN88US=> NEDRPYRUSU6JRWK=
HT-3 NVPWU5lLT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NVnJSpNVUUN3ME2xPE46QDNizszN NH7yOY9USU6JRWK=
BOKU MYjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NXv3WGtuUUN3ME2xPU4xOzhzIN88US=> MVnTRW5ITVJ?
HPAF-II MkHHS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MWrJR|UxRTF7LkOwNVUh|ryP M2nyPHNCVkeHUh?=
KGN NHXPPYJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M3zYc2lEPTB;MUmuOFc3PSEQvF2= NV[xUXR[W0GQR1XS
MC-CAR NXfqTVJ{T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= Mkn2TWM2OD1zOT62N|E{KM7:TR?= MmSxV2FPT0WU
BHT-101 NFrVcVlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M1L0cGlEPTB;MUmuO|c4KM7:TR?= M4nZW3NCVkeHUh?=
SW1783 NIKwU21Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MnfSTWM2OD1zOT63PFA3KM7:TR?= M4D5RXNCVkeHUh?=
KP-N-YN MXLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MYfJR|UxRTJyLkCyOlIh|ryP MYXTRW5ITVJ?
LU-165 M4HMXGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NHSwbYdKSzVyPUKwMlU2PzFizszN NIC2NoRUSU6JRWK=
GOTO MWjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MWPJR|UxRTJyLk[0OVEh|ryP NF\JboZUSU6JRWK=
EFM-19 M1TJXGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MWXJR|UxRTJzLkC3NVYh|ryP MVjTRW5ITVJ?
CTV-1 MkHWS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NYXxd2VrUUN3ME2yNU4yODV2IN88US=> MlHOV2FPT0WU
HEL M4T4e2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NFjxTVBKSzVyPUKxMlQzOTZizszN M4faenNCVkeHUh?=
SNU-C2B NV:y[Y5iT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NW[ycINZUUN3ME2yNU41OjZizszN NHfXbFZUSU6JRWK=
ECC4 M3fNemdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 Ml2wTWM2OD1{MT63NFch|ryP NEj6WpRUSU6JRWK=
NEC8 M{LuTGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MYnJR|UxRTJzLkizOlgh|ryP NGe0V4RUSU6JRWK=
KMOE-2 M4rU[Wdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 Mo\nTWM2OD1{MT64PVIyKM7:TR?= NVL4Tmo6W0GQR1XS
NCI-H524 M1jiRmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MY\JR|UxRTJ{LkC4NFgh|ryP MnOwV2FPT0WU
WSU-NHL NEfYV2ZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NYC5cXlCUUN3ME2yNk4yPTd5IN88US=> NXjOWHA5W0GQR1XS
SF126 NYH2bm9oT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NWq3e5UxUUN3ME2yNk4zPDZ7IN88US=> M4LpOnNCVkeHUh?=
HOP-92 NGnoTYRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NV3zcJhlUUN3ME2yNk4{OTZ5IN88US=> MmPoV2FPT0WU
CTB-1 M2XQUGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MYDJR|UxRTJ{LkS2O|ch|ryP MlHEV2FPT0WU
KYSE-270 NGriR2dIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MVXJR|UxRTJ{LkmzOVch|ryP M4PwUXNCVkeHUh?=
SK-MEL-24 MlfqS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MXrJR|UxRTJ|LkG4O{DPxE1? NXvxdYxmW0GQR1XS
Calu-3 MWLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NEDy[ndKSzVyPUKzMlIyOjhizszN MUjTRW5ITVJ?
GAMG MV;Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NYm4N2ttUUN3ME2yN{4zOzZ5IN88US=> MmDFV2FPT0WU
SW1573 NUnUblU1T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= Ml7oTWM2OD1{Mz63OFE2KM7:TR?= Mmm5V2FPT0WU
MHH-NB-11 NYWwSG5ST3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NUfVbmI2UUN3ME2yOE4xOTl2IN88US=> NUjoOJJRW0GQR1XS
TK10 MX7Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M1yyemlEPTB;MkSuOVAyOyEQvF2= MlPYV2FPT0WU
LB373-MEL-D NF\tRW1Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NX7JbFNzUUN3ME2yOE43ODZ2IN88US=> M4jER3NCVkeHUh?=
KALS-1 NG\iN|dIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NEDHWFhKSzVyPUK0Mlc{OjdizszN M{nDTnNCVkeHUh?=
HUTU-80 Ml7RS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MWrJR|UxRTJ3LkiwN|Ih|ryP NXL6O2Q3W0GQR1XS
HuP-T3 NVfZNolzT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M4nOOmlEPTB;Mk[uNVY4PCEQvF2= M3vWbHNCVkeHUh?=
OE19 MVfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NUn5doVuUUN3ME2yOk4zOTV|IN88US=> M1;MOnNCVkeHUh?=
J82 MYrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MVrJR|UxRTJ4LkK0O|Eh|ryP MY\TRW5ITVJ?
DU-4475 M4DPOGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 Mk\qTWM2OD1{Nj6zPFE6KM7:TR?= M1rOWXNCVkeHUh?=
DMS-53 Ml70S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NUHMRZJxUUN3ME2yOk42OTN6IN88US=> MkLxV2FPT0WU
COLO-741 MYPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NESxSmJKSzVyPUK2Mlg{PDRizszN NGK2[plUSU6JRWK=
SW48 M4nh[Wdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NELHe|NKSzVyPUK2Mlg5OiEQvF2= Ml;jV2FPT0WU
IGR-1 MV3Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NVy1Omk{UUN3ME2yOk46OzN2IN88US=> M3PpW3NCVkeHUh?=
639-V NEP4[HJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NWfMcohXUUN3ME2yO{4xOjR3IN88US=> NF7KSVVUSU6JRWK=
LK-2 MnviS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M1r5XWlEPTB;MkeuOFE1OSEQvF2= Mn3ZV2FPT0WU
NCI-H2347 NU\BTWFTT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NXjT[I1qUUN3ME2yO{46Pjl7IN88US=> NHrVcFlUSU6JRWK=
NCI-H2228 MkLzS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NHjoU4NKSzVyPUK4MlA6ODVizszN M2XOOXNCVkeHUh?=
LS-123 NEnqe4JIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MkfETWM2OD1{OD6xNlYzKM7:TR?= NFXPfZhUSU6JRWK=
U031 NUToeW1yT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M33temlEPTB;MkiuNlUzKM7:TR?= NUP3TG9SW0GQR1XS
NCI-H1792 NIi3Z2tIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MYPJR|UxRTJ6LkS3NlEh|ryP MlLVV2FPT0WU
NCI-H2087 NYXuWoFRT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MmW4TWM2OD1{OD63OVUzKM7:TR?= MX\TRW5ITVJ?
NCI-H2342 Mlf1S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NFfwb|RKSzVyPUK5MlUzODhizszN NUiwTGliW0GQR1XS
SW626 NFPCS2FIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= Mn34TWM2OD1{OT63OVYh|ryP MYfTRW5ITVJ?
LB2518-MEL M1PaPWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NV7yV5E{UUN3ME2yPU45OTVizszN M1mzZnNCVkeHUh?=
RXF393 MWTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M1jlOmlEPTB;M{CuNFk2OiEQvF2= M3y2e3NCVkeHUh?=
LC4-1 M{D1fWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NH32W41KSzVyPUOwMlMxQTJizszN MWDTRW5ITVJ?
NCI-H1694 MYPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NHfrcWJKSzVyPUOwMlY3OjRizszN NI\3cnVUSU6JRWK=
K5 NHG5e2xIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M3\MdWlEPTB;M{CuPVcxOiEQvF2= NGfDS2FUSU6JRWK=
HDLM-2 MmrsS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NGHU[mRKSzVyPUOwMlk4OjVizszN M{nZT3NCVkeHUh?=
BCPAP NYTZVINiT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M{\5bGlEPTB;M{GuPFM4QSEQvF2= M2DIcHNCVkeHUh?=
BC-3 NXu1NZRHT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= Mor2TWM2OD1|Mj6xOFA{KM7:TR?= MYjTRW5ITVJ?
LB996-RCC NGHhW|lIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M3:2ZWlEPTB;M{KuNlM2QCEQvF2= NHWxNoJUSU6JRWK=
NCI-H2009 NFPwXZlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MXjJR|UxRTN{LkS5PFEh|ryP MoC1V2FPT0WU
HTC-C3 MWLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NF;KSVRKSzVyPUOzMlc2OTlizszN MnixV2FPT0WU
LAMA-84 NW\uR41UT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M{PnOWlEPTB;M{SuOFQxPyEQvF2= M3jJbXNCVkeHUh?=
CCRF-CEM MW\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M1HQWGlEPTB;M{SuOVcyPSEQvF2= M1z5XHNCVkeHUh?=
AN3-CA M{LTZWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 Ml64TWM2OD1|NT6wOVY5KM7:TR?= NX;EUnRkW0GQR1XS
NCI-H1734 NFPkT4lIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MY\JR|UxRTN3LkK1OlEh|ryP MmPUV2FPT0WU
Ca-Ski NWmySHpZT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MWTJR|UxRTN3LkSxNFEh|ryP MlzXV2FPT0WU
U-266 MXnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M4npbWlEPTB;M{WuOlEyPCEQvF2= NWLISYs1W0GQR1XS
SBC-5 NH\UVIhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MWHJR|UxRTN3Lke3PFEh|ryP NILw[mRUSU6JRWK=
GT3TKB NHi4cJNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MWHJR|UxRTN5LkGxOUDPxE1? M1XLSHNCVkeHUh?=
MDA-MB-175-VII MVPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NUS2[4s{UUN3ME2zO{4zOjR6IN88US=> NXr3VVM3W0GQR1XS
PFSK-1 MmnJS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MWXJR|UxRTN5LkK0N|Uh|ryP M3PPXXNCVkeHUh?=
IMR-5 Mn7nS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NYj5TWViUUN3ME2zO{4zPDh5IN88US=> NUjQbpNjW0GQR1XS
Daudi NGP3d2hIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MkjxTWM2OD1|Nz6zOVk4KM7:TR?= MnrGV2FPT0WU
A498 NF7kZ4xIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NEfvNJpKSzVyPUO3MlczOThizszN MX7TRW5ITVJ?
SCC-4 NEXuRnhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MYrJR|UxRTN5Lke4OFMh|ryP M1PqPHNCVkeHUh?=
COLO-680N MYDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MnPUTWM2OD1|OD6yPFg2KM7:TR?= Mn\OV2FPT0WU
SK-MES-1 NWnEfHdOT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MYnJR|UxRTN6LkOyNVUh|ryP MXHTRW5ITVJ?
SR MkLTS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NUDsdHl6UUN3ME2zPE42PDl3IN88US=> Mki2V2FPT0WU
LNCaP-Clone-FGC MkT4S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NWq5XFhFUUN3ME2zPE42PjN5IN88US=> M1zBTnNCVkeHUh?=
SK-HEP-1 MXvHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NVnZdJZ{UUN3ME2zPE44QDJ{IN88US=> NV3CS4lFW0GQR1XS
BPH-1 NUPBcIt1T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MYnJR|UxRTN6LkizNlkh|ryP NHq4U4dUSU6JRWK=
NCI-H1755 MoDKS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NUnkTXMzUUN3ME2zPU42QDF5IN88US=> NE\pSoVUSU6JRWK=
LXF-289 M2H1emdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NYrs[2ZDUUN3ME2zPU45ODh2IN88US=> MVzTRW5ITVJ?
SW1088 MlHlS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MoDsTWM2OD12MD6yNVA4KM7:TR?= NXvHfIxtW0GQR1XS
MOLT-4 MnSyS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NXzW[Xp[UUN3ME20NE4zQTBzIN88US=> MV;TRW5ITVJ?
AsPC-1 NVP0bJUxT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NI\WfG1KSzVyPUSwMlQ2QDNizszN MU\TRW5ITVJ?
HOP-62 Ml\hS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MYTJR|UxRTRyLk[1Olgh|ryP Mn;RV2FPT0WU
A172 MWjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NWjnbVlSUUN3ME20NE45PTFzIN88US=> NIfa[3pUSU6JRWK=
SN12C MYHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MYnJR|UxRTRyLkmzPFUh|ryP M4XQTHNCVkeHUh?=
MDA-MB-231 NYfEfJJNT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NHvKOFdKSzVyPUSwMlk5QThizszN NVHWV45vW0GQR1XS
RPMI-2650 MWTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MV7JR|UxRTRzLkG1PVMh|ryP MojnV2FPT0WU
KYSE-140 MUPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NVnIXlE1UUN3ME20NU45OTJ|IN88US=> NHPSVIlUSU6JRWK=
KINGS-1 NIXQRYFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MmPJTWM2OD12Mj60Olk4KM7:TR?= MVnTRW5ITVJ?
HSC-3 MU\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NFnj[JlKSzVyPUSyMlY3PjFizszN MlrLV2FPT0WU
PC-14 NF7nTINIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NEnzVZVKSzVyPUSzMlE5QDJizszN NYTGWmpCW0GQR1XS
COR-L105 MoXCS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M1vBRWlEPTB;NEOuOlUxOiEQvF2= MoX3V2FPT0WU
BE-13 M{DsNmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MnG4TWM2OD12ND6yN|cyKM7:TR?= NGHXSHBUSU6JRWK=
NCI-H661 M13XTWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NYH1T5poUUN3ME20OE4zQTV6IN88US=> M4DrZnNCVkeHUh?=
IST-MEL1 MYfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M2XNU2lEPTB;NESuN|U6QSEQvF2= Ml;ZV2FPT0WU
HCC1806 NWHmXYg6T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NGO4c3JKSzVyPUS0MlU5PzNizszN MUnTRW5ITVJ?
COLO-800 Mn7yS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NHfJWYNKSzVyPUS0Mlg1PTNizszN NHTyT5dUSU6JRWK=
IST-SL2 NX\XR2FUT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M1j2PGlEPTB;NEWuNVI1PyEQvF2= NEGyTWNUSU6JRWK=
8305C MWnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NV7XZ2xVUUN3ME20OU4{ODlizszN NGjxVHJUSU6JRWK=
UACC-62 M4HhUGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NXTZNnlrUUN3ME20Ok4zQDd3IN88US=> MkXoV2FPT0WU
COR-L23 NHPBflFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M1\lW2lEPTB;NEeuNVk6KM7:TR?= MoP0V2FPT0WU
EFE-184 MVPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MVXJR|UxRTR5LkO4PEDPxE1? MkLnV2FPT0WU
DMS-114 NV3EemtVT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NXviV2xEUUN3ME20O{41OTR7IN88US=> MUjTRW5ITVJ?
KYSE-520 NGjYeGdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M2rXUWlEPTB;NEiuOVMyPSEQvF2= Mn\UV2FPT0WU
SNG-M M4T5Xmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NHqxXJpKSzVyPUS5MlQ{PCEQvF2= NF\ieGdUSU6JRWK=
A2058 M3fjPWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M3;FdGlEPTB;NEmuOFg5PSEQvF2= MoD3V2FPT0WU

... Click to View More Cell Line Experimental Data

Assay
Methods Test Index PMID
Western blot
p-EGFR / EGFR / p-IGF1R / IGF1R / p-IRS1 / IRS1 / p-ERK / ERK / p-AKT / AKT; 

PubMed: 26052929     


Effects of linsitinib on EGFR and IGF1R Signaling Pathways. H1975, AR1, AR2 and AR3 cells were treated with control DMSO or linsitinib (2 and 5 μM) for 24 hours. Cell lysates were subjected to Western blot analysis. IGF1R-IRS-1-AKT phosphorylation was effectively inhibited by linsitinib in afatinib resistance cells whereas IRS-1-AKT phosphorylation was up-regulated by linsitinib in H1975 parental cells.

p-IGF1R / IGF1R / p-mTOR / mTOR ; 

PubMed: 28440057     


Linsitinib inhibits the activation of ERK and PI3K pathways. After treatment of Linsitinib at 0.1 or 1.0 μmol/L for 72 h, the phosphorylation of insulin‐like growth factor‐1 receptor (IGF‐1R), ERK1/2, and AKT/mTOR pathways were analyzed in TE‐13, TE‐1, and KYSE‐510 cell lines by western blot.

cleaved caspase-3 / cleaved PARP; 

PubMed: 28440057     


Reduced apoptosis in Linsitinib-resistant esophageal squamous cell carcinoma cells. After treatment of Linsitinib at 0.1 or 1.0 μmol/L for 72 h, cleaved PARP and activated Caspase‐3 were examined in TE-13, TE-1, and KYSE-510 cells by western blot. Tubulin was used as a loading control.

pSrc(Y416) / Src; 

PubMed: 26515601     


A549, H226Br, and H1975 cells were treated with 1 or 2 μM linsitinib (diluted in RPMI 1640 medium containing 10% FBS) for 12 or 24 h. Before harvest, cells were further stimulated with 10% FBS for 20 min. Cells were lysed with modified RIPA buffer and the protein expression was determined by Western blot analysis.

p-STAT3(Y705) / STAT3 ; 

PubMed: 26041671     


H226B and H460 cells were subject to daily treatment with linsitinib (1 μM) for 1-5 days.

pS6 / S6; 

PubMed: 21257723     


Western blot of NCI-H292 cells following 30 minutes of exposure to OSI-906 shows target inhibition of pIGF-1R and pIR at all doses as well as inhibition of downstream targets pAKT and pS6.

26052929 28440057 26515601 26041671 21257723
Immunofluorescence
FoxO1; 

PubMed: 27535223     


After starvation, control or βIRKO β-cell lines were treated with insulin (10 nm) in combination with high glucose (450 mg/dL), in the presence or absence of PI3K inhibitor LY294002, insulin receptor, and IGF1 receptor dual inhibitor OSI-906, Akt inhibitor MK2206, or MEK1/2 inhibitor U0126 for 30 min.  A, representative pictures of β-cells immunostained for FoxO1 (red) and DAPI (blue). The scale bar indicates 20 μm.

27535223
Growth inhibition assay
Cell viability; 

PubMed: 26136493     


InsR/IGF1R dual inhibitors, OSI-906 and BMS-754807, dose-dependently inhibited T4105 viability.

26136493
In vivo OSI-906 inhibits tumor growth in an IGF-1R-driven xenograft mouse model, with 100% TGI and 55% regression at a dose of 75 mg/kg and 60% TGI and no regression at a dose of 25 mg/kg. OSI-906 administration induces different elimination half-lives of itself in dog, rat and mice, the elimination half-lives are 1.18 hours, 2.64 hours and 2.14 hours, respectively. OSI-906 administration at different single dose once-daily in femal Sprague-Dawley rat and femal CD-1 mouse reveal that the Vmax is not dose-proportional to OSI-906 dose. OSI-906 elevates the blood glucose levels at a dose of 25 mg/kg after 12 days administration. OSI-906 administration at a single dose of 75 mg/kg in IGF-1R-driven full-length human IGF-1R (LISN) xenograft mouse model achieve maximal inhibition of IGF-1R phosphorylation (80%) between 4 and 24 hours with plasma drug concentrations of 26.6-4.77 μM. [1] OSI-906 administered as a single dose of at 60 mg/kg in NCI-H292 xenografts mice inhibits uptake of glucose at 2, 4, and 24 hours post-treatment in vivo. OSI-906 inhibits the growth of tumors in NCI-H292 xenograft mouse model. [2]

Protocol

Kinase Assay:[1]
- Collapse

Protein kinase biochemical assays:

Protein kinase assays are either performed in-house by ELISA-based assay methods (IGF-1R, IR, EGFR and KDR) or at Upstate Inc. by a radiometric method with ATP at 100 µM concentration. In-house ELISA assays use poly(Glu:Tyr) as the substrate bound to the surface of 96-well assay plates and phosphorylation is detected using an antiphosphotyrosine antibody conjugated to horseradish peroxidase. The bound antibody is quantified using ABTS as the peroxidase substrate by measuring absorbance at 405 / 490 nm. All assays use purified recombinant kinase catalytic domains. Recombinant enzymes of human IGF-1R or EGFR are expressed as an NH2-terminal glutathione S-transferase fusion protein in insect cells and are purified in house. IC50 values are determined from the sigmoidal dose–response plot of percent inhibition versus log10 compound concentration. A minimum of three measurements, performed in duplicate, are carried out with in-house assays unless otherwise indicated. OSI-906 at a concentration of 1 µM is profiled versus a panel of kinases using the ProfilerProTM Kinase Selectivity Assay Kit.
Cell Research:[1]
- Collapse
  • Cell lines: MCF7, NCI-H292, Colo-205, HT29, H358, H1703, BxPC3, A673, SW620, DU4475, HepG2 and Hepa-1, RKO 3T3/hulGF-IR and H292 cells
  • Concentrations: 0.02-0.8 μM
  • Incubation Time: 3 days
  • Method: For assays of cell proliferation, cells are seeded into 96-well plates in appropriate media containing FCS 10% and incubated for 3 days in the presence of OSI-906 at various concentrations. Inhibition of cell growth is determined by luminescent quantitation of intracellular ATP content using CellTiterGlo. Data is presented as a fraction of maximal proliferation, calculated by dividing the cellular density in the presence of varying concentrations of OSI-906 by the cellular density of control cells treated with vehicle (DMSO) only.
    (Only for Reference)
Animal Research:[1]
- Collapse
  • Animal Models: IGF-1R-driven full-length human IGF-1R (LISN) xenograft mouse model
  • Formulation: 25 mM tartaric acid
  • Dosages: 25 mg / kg and 75 mg / kg
  • Administration: Orally administrated at once-daily oral dose for 14 days
    (Only for Reference)

Solubility (25°C)

In vitro DMSO 84 mg/mL (199.29 mM)
Water Insoluble
Ethanol Insoluble
In vivo Add solvents to the product individually and in order(Data is from Selleck tests instead of citations):
5%DMSO+40%PEG300+5%Tween80+50%ddH2O
For best results, use promptly after mixing.
6.25mg/mL

* Please note that Selleck tests the solubility of all compounds in-house, and the actual solubility may differ slightly from published values. This is normal and is due to slight batch-to-batch variations.

Chemical Information

Molecular Weight 421.49
Formula

C26H23N5O

CAS No. 867160-71-2
Storage powder
in solvent
Synonyms N/A
Smiles CC1(O)CC(C1)C2=NC(=C3[N]2C=CN=C3N)C4=CC=C5C=CC(=NC5=C4)C6=CC=CC=C6

Bio Calculators

Molarity Calculator

Molarity Calculator

Calculate the mass, volume or concentration required for a solution. The Selleck molarity calculator is based on the following equation:

Mass (mg) = Concentration (mM) × Volume (mL) × Molecular Weight (g/mol)

  • Mass
    Concentration
    Volume
    Molecular Weight

*When preparing stock solutions, please always use the batch-specific molecular weight of the product found on the via label and MSDS / COA (available on product pages).

Dilution Calculator

Dilution Calculator

Calculate the dilution required to prepare a stock solution. The Selleck dilution calculator is based on the following equation:

Concentration (start) x Volume (start) = Concentration (final) x Volume (final)

This equation is commonly abbreviated as: C1V1 = C2V2 ( Input Output )

  • C1
    V1
    C2
    V2

* When preparing stock solutions always use the batch-specific molecular weight of the product found on the vial label and MSDS / COA (available online).

The Serial Dilution Calculator Equation

  • Serial Dilutions

  • Computed Result

  • C1=C0/X C1: LOG(C1):
    C2=C1/X C2: LOG(C2):
    C3=C2/X C3: LOG(C3):
    C4=C3/X C4: LOG(C4):
    C5=C4/X C5: LOG(C5):
    C6=C5/X C6: LOG(C6):
    C7=C6/X C7: LOG(C7):
    C8=C7/X C8: LOG(C8):
Molecular Weight Calculator

Molecular Weight Calculator

Enter the chemical formula of a compound to calculate its molar mass and elemental composition:

Total Molecular Weight: g/mol

Tip: Chemical formula is case sensitive. C10H16N2O2 c10h16n2o2

Instructions to calculate molar mass (molecular weight) of a chemical compound:

To calculate molar mass of a chemical compound, please enter its chemical formula and click 'Calculate'.

Definitions of molecular mass, molecular weight, molar mass and molar weight:

Molecular mass (molecular weight) is the mass of one molecule of a substance and is expressed in the unified atomic mass units (u). (1 u is equal to 1/12 the mass of one atom of carbon-12)
Molar mass (molar weight) is the mass of one mole of a substance and is expressed in g/mol.

Molarity Calculator

Mass Concentration Volume Molecular Weight

Clinical Trial Information

NCT Number Recruitment interventions Conditions Sponsor/Collaborators Start Date Phases
NCT02546544 Completed Drug: Linsitinib Relapsed Ewing Sarcoma|Refractory Ewing Sarcoma University of Oxford|European Organisation for Research and Treatment of Cancer - EORTC|European Commission|Astellas Pharma Inc|Oxford University Hospitals NHS Trust March 2014 Phase 2
NCT01672736 Terminated Drug: ASP7487 Velcade Dexamethasone Multiple Myeloma University Health Network Toronto|Multiple Myeloma Research Consortium|Astellas Pharma Inc September 2012 Phase 1|Phase 2
NCT01529684 Completed Drug: radio-labeled OSI-906|Drug: OSI-906 Advanced Solid Tumors|Pharmacokinetics of 14C-OSI-906 Astellas Pharma Global Development Inc.|Astellas Pharma Inc March 19 2012 Phase 1
NCT01221077 Completed Drug: OSI-906|Drug: Erlotinib|Drug: Placebo NSCLC|Non Small Cell Lung Cancer Astellas Pharma Inc April 8 2011 Phase 2

Tech Support

Answers to questions you may have can be found in the inhibitor handling instructions. Topics include how to prepare stock solutions, how to store inhibitors, and issues that need special attention for cell-based assays and animal experiments.

Handling Instructions

Tel: +1-832-582-8158 Ext:3

If you have any other enquiries, please leave a message.

  • * Indicates a Required Field

Frequently Asked Questions

  • Question 1:

    Does the inhibitor dissolve in the vehicle (30% PEG400/0.5%Tween 80/5% propylene glycol) or is it a suspension?

  • Answer:

    OSI-906 in 30% PEG400/0.5%Tween 80/5% propylene glycol is a suspension.

IGF-1R Signaling Pathway Map

IGF-1R Inhibitors with Unique Features

Related IGF-1R Products

Tags: buy Linsitinib (OSI-906) | Linsitinib (OSI-906) supplier | purchase Linsitinib (OSI-906) | Linsitinib (OSI-906) cost | Linsitinib (OSI-906) manufacturer | order Linsitinib (OSI-906) | Linsitinib (OSI-906) distributor
×
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID